Diabetes, Vol 39, Issue 3 299-304, Copyright © 1990 by American Diabetes Association

ARTICLES

Renal kallikrein and hemodynamic abnormalities of diabetic kidney

JN Harvey, AA Jaffa, HS Margolius and RK Mayfield
Department of Medicine, Medical University of South Carolina, Charleston.

The relationship between renal hemodynamic abnormalities and renal kallikrein activity was studied in streptozocin-induced diabetic rats. Diabetic rats were either not treated with insulin and had plasma glucose levels greater than 400 mg/dl (severely hyperglycemic diabetic [SD]) or were treated with 1.5-1.75 U/day protamine zinc insulin and had glucose levels of 200-300 mg/dl (moderately hyperglycemic diabetic [MD]). In SD rats, kidney tissue level and excretion of active kallikrein were reduced after 3 wk compared with age-matched nondiabetic control rats (tissue, 11.7 +/- 1.9 vs. 20.5 +/- 1.8 ng/mg protein, P less than 0.005; urine, 126 +/- 12 vs. 179 +/- 10 micrograms/24 h, P less than 0.005). Despite increased kidney size, renal plasma flow (RPF) was reduced in SD rats (5.38 +/- 0.23 vs. 6.37 +/- 0.20 ml/min, P less than 0.05). Glomerular filtration rate (GFR) was not significantly lower (2.77 +/- 0.60 vs. 3.02 +/- 0.56 ml/min). In MD rats, kidney tissue level and excretion of active kallikrein were increased after 5 wk compared with age-matched nondiabetic control rats (tissue, 28.4 +/- 1.3 vs. 23.3 +/- 1.7 ng/mg protein, P less than 0.05; urine, 289 +/- 16 vs. 196 +/- 13 micrograms/24 h, P less than 0.001). In MD rats, GFR and RPF were increased (3.80 +/- 0.11 and 8.04 +/- 0.17 ml/min, respectively) compared with control rats (3.22 +/- 0.05 and 7.28 +/- 0.09 ml/min, P less than 0.001).(ABSTRACT TRUNCATED AT 250 WORDS)
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				Y. Tan, J.-S. Keum, B. Wang, M. B. McHenry, S. R. Lipsitz, and A. A. Jaffa Targeted deletion of B2-kinin receptors protects against the development of diabetic nephropathy Am J Physiol Renal Physiol, October 1, 2007; 293(4): F1026 - F1035. [Abstract] [Full Text] [PDF]

				G. Yuan, J. Deng, T. Wang, C. Zhao, X. Xu, P. Wang, J. W. Voltz, M. L. Edin, X. Xiao, L. Chao, et al. Tissue Kallikrein Reverses Insulin Resistance and Attenuates Nephropathy in Diabetic Rats by Activation of Phosphatidylinositol 3-Kinase/Protein Kinase B and Adenosine 5'-Monophosphate-Activated Protein Kinase Signaling Pathways Endocrinology, May 1, 2007; 148(5): 2016 - 2026. [Abstract] [Full Text] [PDF]

				Y. Tan, B. Wang, J.-S. Keum, and A. A. Jaffa Mechanisms through which bradykinin promotes glomerular injury in diabetes Am J Physiol Renal Physiol, March 1, 2005; 288(3): F483 - F492. [Abstract] [Full Text] [PDF]

				A. A. Jaffa, R. Durazo-Arvizu, D. Zheng, D. T. Lackland, S. Srikanth, W. T. Garvey, and A. H. Schmaier Plasma Prekallikrein: A Risk Marker for Hypertension and Nephropathy in Type 1 Diabetes Diabetes, May 1, 2003; 52(5): 1215 - 1221. [Abstract] [Full Text] [PDF]

				A. A. Jaffa, B. S. Miller, S. A. Rosenzweig, P. S. Naidu, V. Velarde, and R. K. Mayfield Bradykinin induces tubulin phosphorylation and nuclear translocation of MAP kinase in mesangial cells Am J Physiol Renal Physiol, December 1, 1997; 273(6): F916 - F924. [Abstract] [Full Text] [PDF]

				H. S. Margolius Kallikreins and Kinins : Some Unanswered Questions About System Characteristics and Roles in Human Disease Hypertension, August 1, 1995; 26(2): 221 - 229. [Abstract] [Full Text]